ArticleDiscover oncology2025
Bibliometric analysis of immune dysregulation and immunotherapy in mismatch repair-deficient colon cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMismatch repair deficiency (dMMR) is observed in 12-15% of sporadic colon carcinomas. dMMR tumors have unique genetic characteristics, with mutation rates 10 to 100 times higher than those of tumors with intact mismatch repair functions. Approximately 15% of colon cancer cases exhibit mismatch repair deficiency. Moreover, the status of DNA mismatch repair deficiency holds prognostic and predictive significance in both non-metastatic and metastatic colon cancer. Therefore, we aim to comprehensively conduct a bibliometric analysis of research on mismatch repair-deficient colon cancer studies to identify research trends and potential future directions.
methodsA total of 1428 relevant articles from January 1, 1995 to July 1, 2024 were obtained from the Web of Science Core Collection. Knowledge graphs were analyzed and visualized using VOSviewer, CiteSpace, and Scimago Graphica software as bibliometric tools to extract or calculate evaluation metrics. Publications were categorized by country, institution, author, journal, highly cited article, and keyword. These variables were compared in terms of publication and academic impact, including citation count, citation impact, H-index, and journal impact factor.
resultsA total of 1428 publications related to mismatch repair-deficient colon cancer were retrieved from 351 countries and 6953 research institutions. The United States and China led the way in terms of the number of publications and impact; the most prolific institution was Sun Yat-sen University, followed by the Mayo Clinic; Cancers was the journal with the most publications, while Cancer Research was the most cited journal; André, Thierry was the most prolific author, and Thibodeau, Stephen N. had the highest H-index of all authors; the five most cutting-edge keywords identified were colorectal cancer, microsatellite instability, immunotherapy, Lynch syndrome, and mismatch repair. Among these, topics such as Nivolumab, PD-1 blockade, open label, mismatch repair deficient, immune checkpoint inhibitors, and metastatic colorectal cancer remain the hot topics in this field.
conclusionResearch on mismatch repair-deficient colon cancer is poised to enter a golden age in the coming years. This study not only provides insights into the directions and frontiers of mismatch repair-deficient colon cancer research but also highlights that the treatment of mismatch repair-deficient colon cancer benefits from a multidisciplinary approach. The comparison of different immune-assisted therapies will contribute to a more comprehensive understanding of the therapeutic landscape. Ultimately, large-scale and well-designed clinical trials are required to establish a recognized standard that can benefit more patients with mismatch repair-deficient colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.